Autophagy, a tightly regulated lysosome-dependent catabolic pathway, is important in the regulation of cancer development and progression and in determining the response of tumor cells to anticancer therapy. However, the role of autophagy in leukemia still remains largely unknown. Here we show that high-mobility group box 1 (HMGB1), the best characterized damage-associated molecular pattern, was released from leukemia cell lines after chemotherapy-induced cytotoxicity and activated autophagy to protect against injury. Treatment with HMGB1-neutralizing antibodies increased the sensitivity of leukemia cells to chemotherapy; whereas, exogenous HMGB1 rendered these cells more resistant to drug-induced cytotoxicity. Moreover, exogenous HMGB1 increased autophagy as evaluated by increased expression of the autophagic marker microtubule-associated protein light chain 3-II, degradation of sequestosome 1 (p62) and autophagosome formation. Furthermore, knockdown or pharmacological inhibition of either phosphoinositide 3-kinase-III or extracellular signal-regulated kinase kinase mitogen-activated protein kinase kinase/extracellular signal-regulated protein kinase inhibited HMGB1-induced autophagy. Taken together, these results suggest that HMGB1 release after chemotherapy is a critical regulator of autophagy and a potential drug target for therapeutic interventions in leukemia.
Introduction
Autophagy, a process in which subcellular membranes undergo dynamic morphological changes that result in the degradation of cellular proteins and cytoplasmic organelles, is implicated in many physiological and pathophysiological conditions. 1 During this process, cytosolic constituents are sequestered into autophagosomes, which subsequently fuse with lysosomes to become autolysosomes in which, their contents are degraded. 2 Although constitutive autophagy is a homeostatic mechanism for intracellular recycling and energy homeostasis, the upregulation of autophagy in response to stress is an important mechanism for the removal of damaged proteins and organelles. [3] [4] [5] Autophagy thereby confers stress tolerance, limits damage and sustains viability under adverse conditions. Defects in autophagy have been implicated in many diseases including neurodegeneration, ageing, liver disease and, importantly, cancer. 1, 3, 4 Moreover, autophagy has been demonstrated as important for conferring resistance to chemotherapy, radiation therapy and immunotherapy in cancer cells. 3, 4 However, the exact molecular mechanism by which autophagy induces drug resistance in cancer cells, specifically leukemia cells, has not been clearly defined.
High-mobility group box 1 (HMGB1), a highly conserved nuclear protein, acts as a chromatin-binding factor that bends DNA and promotes access to transcriptional protein assemblies on specific DNA targets. In addition to its nuclear role, HMGB1 also functions as an extracellular signaling molecule during inflammation, cell differentiation, cell migration, tumor development and tumor progression through its interactions with the receptor for advanced glycation end products and tolllike receptors. [6] [7] [8] HMGB1, along with other intracellular factors released from tumor cells in response to chemotherapy or radiotherapy, is an important component of the disordered tumor microenvironment. 9 In the tumor microenvironment, HMGB1 recognition has a paradoxical effects on tumor immunity: it promotes tumor neoangiogenesis, but also triggers a protective antineoplastic T-cell response. 10 Moreover, receptor for advanced glycation end products and HMGB1 sustain autophagy and limits apoptosis, promoting pancreatic and colon tumor cell survival. [11] [12] [13] We have previously demonstrated that endogenous HMGB1 is a negative regulator of apoptosis in leukemia cells. 14, 15 Overexpression of HMGB1 by gene transfection rendered leukemia cells resistant to apoptosis; whereas suppression of HMGB1 expression by RNA interference increased the sensitivity of leukemia cells to chemotherapeutic drugs. 14, 15 However, the function of HMGB1 released from leukemia cells in response to chemotherapy was previously unknown. Here, we demonstrate that HMGB1-neutralizing antibodies enhanced the cytotoxic effects of chemotherapy, whereas exogenous HMGB1 enhanced drug resistance in leukemia cells. Furthermore, our data suggest a role for exogenous HMGB1 in the regulation of autophagy through the phosphoinositide 3-kinase (PI3K)-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway, supporting the notion that HMGB1 is a potential drug target for therapeutic interventions in leukemia.
Materials and methods

Reagents
The antibodies to HMGB1, LC3 and p62 were obtained from Novus (Littleton, CO, USA). The antibodies to class III phosphoinositide 3-kinase (PI3K-III), Phospho-extracellular signalregulated kinase 1 and 2 (ERK1/2), ERK1/2, MEK1/2, tubulin, actin, Beclin1, Bcl-2, Atg-5 and Atg-12 were obtained from Cell Signaling 
Cell culture
The human leukemia cell line, HL-60 and Jurkat from American Type Culture Collection (Manassas, VA, USA) were cultured in Iscove's modified Dulbecco's medium or RPMI-1640 medium (Invitrogen, San Diego, CA, USA) with 10% heat-inactivated fetal bovine serum, 2 mM glutamine and antibiotic-antimycotic mix in a humidified incubator with 5% CO 2 and 95% air.
Measurements of HMGB1 release
Human HMGB1 released into cell culture supernatants was evaluated using ELISA kits from Shino-Test Corporation (Sagamihara-shi, Kanagawa, Japan) according to the manufacturer's instructions.
RNA interference
Short hairpin RNA (shRNA) against human Beclin1, PI3K-III, HMGB1 and MEK1/2 were obtained from Sigma and were transfected into cells using the Lipofectamine 2000 reagent (Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. Human MEK1/2 small interfering RNA and control small interfering RNA were obtained from Santa Cruz Technology. The RNA interference oligonucleotides were transfected into cells by using Lipofectamine RNA interference MAX according to the manufacturer's protocols. 16 
Cell viability assay
Cells were plated at a density of 5 Â 10 4 cells/well in 96-well plates in 100 ml medium. After treatment, cell viability was evaluated using the Cell Counting Kit-8 (Dojindo Laboratories, Tokyo, Japan) according to the manufacturer's instructions. In parallel, analysis of cell viability by trypan blue exclusion assay was performed and yielded similar results (data not shown).
Western blotting analysis
Cells were lysed in 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA and 1% Tergitol-type NP-40 supplemented with a protease inhibitor (Complete Mini EDTA-free; Roche, Indianapolis, IN, USA) and phosphatase inhibitor mixture II (Sigma). 17, 18 In all, 30 mg of protein per lane was run on a denaturing 10% SDSpolyacrylamide gel and subsequently transferred to polyvinylidene fluoride membranes via semidry transfer. After blocking the membrane at room temperature for 3 h, the membrane was incubated overnight at 4 1C with various primary antibodies. After incubation with peroxidase-conjugated secondary antibodies for 1 h at 25 1C, the signals were visualized using enhanced chemiluminescence (Pierce, Rockford, IL, USA).
Immunofluorescence analysis
Cells were fixed in 4% formaldehyde for 30 min at room temperature before cell permeabilization with 0.1% Triton X-100 (4 1C, 10 min). Cells were saturated with phosphate-buffered saline containing 2% bovine serum albumin for 1 h at room temperature and processed for immunofluorescence with anti-LC3 antibody followed by Alexa Fluor 488-conjugated immunoglobulin and Hoechst 33258 (Invitrogen). Between all incubation steps, cells were washed three times for 3 min with phosphate-buffered saline containing 0.2% bovine serum albumin. Fluorescence signals were analyzed using an Olympus Fluoview 1000 confocal microscope (Olympus Corp, Tokyo, Japan). The average LC3 punctae per cell from at least 100 cells was determined using Image-Pro Plus 5.1 software (Media Cybernetics, Bethesda, MD, USA).
Immunoprecipitation analysis
Cells were lysed at 4 1C in ice-cold radioimmunoprecipitation assay lysis buffer (Millipore, Billerica, MA, USA), and cell lysates were cleared by a brief centrifugation (12 000 g, 10 min). Concentrations of proteins in the supernatant were determined by bicinchoninic acid assay. Before immunoprecipitation, samples containing equal amounts of proteins were pre-cleared with Protein A or protein G agarose/sepharose (Millipore) (4 1C, 3 h) and subsequently incubated with various irrelevant immunoglobulin-G or specific antibodies (5 mg/ml) in the presence of protein A or G agarose/sepharose beads for 2 h or overnight at 4 1C while gently shaking. 16, 17, 19 Following incubation, agarose/ sepharose beads were washed extensively with phosphatebuffered saline and proteins eluted by boiling in 2 Â SDS sample buffer before SDS-polyacrylamide gel electrophoresis.
Transmission electron microscopy analysis
Cells were fixed with 2% paraformaldehyde and 2% glutaraldehyde in 0.1 mol/l phosphate buffer (pH 7.4), followed by 1% OsO 4 . After dehydration, thin sections were stained with uranyl acetate and lead citrate for observation under a JEM 1011CX electron microscope (JEOL, Peabody, MA, USA). Images were acquired digitally from a randomly selected pool of 10-15 fields under each condition. The quantification of autophagosomes and autophagolysosomes were performed as previously described. 20 
Statistical analysis
Data are expressed as means±s.d. of three independent experiments. Significance of differences between groups was determined by two-tailed Student's t-test or analysis of variance/ Fisher's least significant difference test. A P-value o0.05 was considered significant.
Results
Inhibition of HMGB1 release increases chemotherapy sensitivity in leukemia cells
To determine the amount of HMGB1 released by cells following treatment with chemotherapy, we quantified HMGB1 in cell culture supernatants by ELISA. Consistent with previous studies, 16 HL-60 and Jurkat leukemia cells treated with several widely used chemotherapeutic drugs used to treat hematological malignancies such as VCR (1 mg/ml), ADM (1 mg/ml), cytosine arabinoside (0.2 mM) and arsenic trioxide (5 mM) demonstrate increased cytotoxicity after 24 h of treatment ( Figure 1a ). Concurrently in HL-60 and Jurkat cells treated for 24 h with these drugs, the concentration of HMGB1 in the supernatants was significantly elevated compared with untreated cells (Figure 1a) . Consistently, treatment with etoposide (30 mg/ml), camptothecin (10 mg/ml), staurosporine (5 mM) and cycloheximide (70 mM) also resulted in HMGB1 release into the supernatant after 24-30 h of treatment HMGB1 and autophagy in leukemia L Liu et al in Jurkat or U937 leukemia cells, 21 suggesting that the release of HMGB1 from leukemia cells is a universal event during exposure to chemotherapy.
To explore the role of HMGB1 release from leukemia cells following chemotherapy, HL-60 and Jurkat leukemia cells were treated with a specific neutralizing antibody against HMGB1. HMGB1-neutralizing antibodies significantly increased the sensitivity of leukemia cells to chemotherapeutics such as VCR and ADM compared with the Immunoglobulin-G control ( Figure 1b) . We previously demonstrated that quercetin prevents HMGB1 release and proinflammatory functions in endotoxemia. 22 Thus, quercetin inhibited VCR and ADM-induced HMGB1 release (data not shown) and increased the sensitivity of leukemia cells to chemotherapy (Figure 1c) . Moreover, knockdown of HMGB1 by specific shRNA in HL-60 and Jurkat cells rendered them significantly more sensitive to anticancer agents (Figure 1d ). These data suggest that HMGB1 release from leukemia cells increases chemotherapeutic drug resistance.
Autophagy is required for exogenous HMGB1-mediated chemotherapy resistance
To further characterize the role of HMGB1 in the regulation of sensitivity to chemotherapy, HL-60 and Jurkat cells were treated with HMGB1 protein (1 mg/ml) for 24 h and then treated with chemotherapeutic drugs (VCR, ADM, Ara-C and arsenic trioxide). Pre-treatment with HMGB1 increased drug resistance in these leukemia cells (Figure 2a) , supporting a potential prosurvival role for HMGB1 in cells exposed to chemotherapy.
Increasing evidence suggests that autophagy is an important resistance mechanism to chemotherapy in hematological malignancies. 4, 5, 23, 24 To explore the potential mechanism of HMGB1-mediated drug resistance in HL-60 and Jurkat cells, we suppressed the expression of Beclin1 (ATG6), which is required for the initiation of the formation of the autophagasome. 2 Knockdown of Beclin1 in these cells reversed HMGB1-induced drug resistance (Figure 2b) . Moreover, pharmacological inhibition of autophagy with bafilomycin A1 2 also reversed HMGB1-mediated drug resistance (Figure 2c ), suggesting that autophagy is required for exogenous HMGB1-mediated chemotherapy resistance in leukemia cells.
HMGB1 induces autophagy in leukemia cells
To investigate whether HMGB1 is a direct activator of autophagic flux, we detected microtubule-associated protein light chain 3 (LC3) conversion (LC3-I-LC3-II) by immunoblot analysis. LC3 is now widely used to monitor autophagy and the (1 mg/ml), ADM (1 mg/ml), cytosine arabinoside (Ara-C, 0.2 mM) or arsenic trioxide (AS 2 O 3 , 5 mM) for 24 h and then the cell viability (top) and HMGB1 release (bottom) was analyzed (n ¼ 3, *Po0.05 versus control group). Cell viability of control was set as 100%. (b, c) HL-60 and Jurkat cells were treated with VCR (1 mg/ml) or ADM (1 mg/ml) for 0-48 h with or without HMGB1-neutralizing antibody ('b', 10 mg/ml) or quercetin ('c', 50 mM), and then cell viability was analyzed (n ¼ 3, *Po0.05 versus control group). Cell viability of control was set as 100%. (d) After transfection with HMGB1 shRNA or control shRNA for 48 h, cells, as indicated, were treated with VCR (1 mg/ml), ADM (1 mg/ml), cytosine arabinoside (Ara-C, 0.2 mM) or arsenic trioxide (AS 2 O 3 , 5 mM) for 24 h, then cell viability was analyzed (n ¼ 3, *Po0.05 versus control shRNA group). Cell viability of control was set as 100%.
HMGB1 and autophagy in leukemia
2 Treatment with exogenous HMGB1 induced a timedependent increase in the expression of LC3-II in leukemia cells (Figure 3a) . However, LC3-II itself is degraded by autophagy, making interpretation of the results of LC3 immunoblotting alone problematic. 2 To further investigate whether HMGB1 influences autophagic flux, we evaluated the expression of sequestosome 1 (p62), a long lived scaffolding protein involved in the transport of ubiquitinylated proteins destined for proteosomal digestion. 25 p62 has LC3 binding domains, which targets this protein for incorporation into the autophagosome therefore, serving as a selective substrate of autophagy. 25 Consistent with increased autophagic flux following treatment with HMGB1, there was a time-dependent decrease in the level of p62 by immunoblotting (Figure 3a) . Moreover, LC3 accumulation following HMGB1 treatment was exaggerated in leukemia cells after treatment with the lysosomal protease inhibitor E64d and pepstatin A (Figure 3b ). These data demonstrate that the observed increase in LC3-II was not because of decreased degradation of lipidated LC3, but rather increased autophagic flux (Figure 3b) . Furthermore, we observed an increase of endogenous LC3 punctae formation after HMGB1 treatment by immunofluorescence analysis (Figure 3c ). Moreover, knockdown of HMGB1 in HL-60 and Jurkat cells inhibited anticancer agent-induced accumulation of LC3 punctae (Figure 3d ), supporting a critical role for HMGB1 in the regulation of autophagy.
An important molecular event in autophagic vesicle nucleation is the formation of the Beclin1-PI3K-III complex and disassociation of the Bcl-2-Beclin1 complex.
2,26 HMGB1 increased the interaction of Beclin1-PI3K-III and suppressed interaction of Beclin1-Bcl-2 (Figure 3e ), suggesting that HMGB1 promotes vesicle nucleation. Moreover, HMGB1 promoted Atg5-Atg12-Atg16 complexes formation (Figure 3f ) and enhanced the accumulation of the Atg5-Atg12-Atg16 complex with LC3 (Figure 3g ), suggesting that HMGB1 contributes to phagophore membrane elongation and autophagosome formation.
The most traditional method for monitoring the number of autophagosomes is electron microscopy. 2 At the ultrastructural level, Type I autophagosomes are defined as double-membraned structures containing undigested cytoplasmic contents, which have not fused with a lysosome. In contrast, Type II autophagolysosomes are hybrid organelles generated by the fusion of autophagosomes and lysosomes, which have single limiting membranes and contain cytoplasmic materials at various stages of degradation. Ultrastructural analysis revealed that HL-60 cells exhibited more Type I autophagosomes and Type II autophagolysosomes after HMGB1 treatment when compared with the untreated group (Figure 3h ).
Class III PI3K is required for HMGB1-induced autophagy
As PI3K-III are required for autophagy initiation, 27 we investigated the role of PI3K-III in the regulation of HMGB1-mediated autophagy using the potent PI3K inhibitor, 3-MA. 3-MA significantly inhibited HMGB1-induced LC3 conversion (LC3-I-LC3-II) and p62 degradation (Figure 4a ). However, 3-MA, which is used at very high concentrations to inhibit autophagy (usually 10 mM), can target other kinases and affect other cellular processes. 2 To further characterize the role of PI3K-III in leukemia cells after HMGB1 treatment, a target-specific shRNA against PI3K-III was transfected into HL-60 and Jurkat leukemia cells. (1 mg/ml) for 24 h and then treated with VCR (1 mg/ml), ADM (1 mg/ml), cytosine arabinoside (Ara-C, 0.2 mM) or arsenic trioxide (AS 2 O 3 , 5mM) for 48 h, then cell viability was analyzed (n ¼ 3, *Po0.05). Cell viability of control was set as 100%. (b) After transfection with Beclin1 shRNA or control shRNA for 48 h, cells were treated with HMGB1 protein (1 mg/ml) for 24 h and then treated with VCR (1 mg/ml) or ADM (1 mg/ml) for 48 h, then cell viability was analyzed (n ¼ 3, *Po0.05). Cell viability of control was set as 100%. (c) HL-60 cells were treated with HMGB1 protein (1 mg/ml, 24 h) with or without bafilomycin A1 ('Baf A1', 100 nM) and then treated with VCR (1 mg/ml), ADM (1 mg/ml), cytosine arabinoside (Ara-C, 0.2 mM) or arsenic trioxide (AS 2 O 3 , 5 mM) for 48 h, then cell viability was analyzed (n ¼ 3, *Po0.05). Cell viability of control was set as 100%.
Transfection of PI3K-III-shRNA led to a significant decrease in PI3K-III protein in these cells (Figure 4b ). Depletion of PI3K-III expression in these cells significantly inhibited HMGB1-induced autophagy (Figure 4b ), suggesting that PI3K-III is required for HMGB1-induced autophagy.
MEK-ERK pathway is required for HMGB1-induced autophagy
The ERK1-2 pathway is involved in many cellular processes such as cell proliferation, differentiation, survival and death, and is an important target in the diagnosis and treatment of leukemia. 28 Extracellular signal-regulated kinase kinase (MEK) functions as an immediate upstream activator of ERK. However, the signaling pathway by which autophagy is induced in response to HMGB1 was previously unclear. We therefore, investigated the role of MEK-ERK pathway in HMGB1-induced autophagy. ERK1/2 was activated by phosphorylation in response to exogenous HMGB1 in leukemia cells (Figure 5a) . Interestingly, the PI3K inhibitor, 3-MA, inhibited HMGB1-induced ERK1/2 phosphorylation, suggesting that ERK maybe a downstream signal of PI3K. Notably, the MEK inhibitor, U0126, and MEK1/2 small interfering RNAs inhibited HMGB1-induced autophagy as evaluated by LC-3 conversion and p62 expression by western blot analysis (Figures 5a and b) .
To further characterize the role of PI3K-III-MEK-ERK in HMGB1-mediated autophagy, we evaluated autophagy by analyzing the accumulation of LC3 punctae in knockdown cells HMGB1 and autophagy in leukemia L Liu et al after treatment with anticancer agents in HL-60 cells (Figure 5c) . Knockdown of HMGB1, PI3K-III or MEK all significantly diminished VCR and ADM-induced autophagy (Figure 5c ). Moreover, knockdown of PI3K-III and/or MEK further enhanced the effect of HMGB1 shRNA on autophagy (Figure 5c ), suggesting that there is crosstalk between the PI3K-III-MEK and HMGB1 pathways. Consistently, knockdown of both PI3K-III and MEK enhanced the effect that the individual PI3K-III, shRNA or MEK shRNA had on HMGB1-induced autophagy (Figure 5d) . Furthermore, ultrastructural analysis demonstrated that knockdown of PI3K-III and MEK in HL-60 cells decreased HMGB1 induced autophagosome formation relative to the control shRNA group (Figure 5e ). Collectively, these data (Figures 4  and 5) indicate that HMGB1 induced autophagy through the PI3K-MEK-ERK pathway ( Figure 6 ).
Discussion
In this study, we demonstrate that a novel function of HMGB1, as a damage-associated molecular pattern, is to regulate chemotherapy sensitivity by inducing autophagy in leukemia cells. Inhibition of HMGB1 using neutralizing antibodies and pharmacological inhibitors of its release significantly enhanced chemotherapy sensitivity, whereas exogenous HMGB1 treatment enhanced drug resistance in leukemia cells.
Acquired resistance to chemotherapy is a major obstacle in successfully treating leukemia. Many mechanisms of drug resistance are well recognized, such as those due to drug export transporters (for example, permeability-glycoprotein), more effective DNA repair mechanisms, altered pharmacokinetics, resistance to apoptosis and resistant hematopoietic stem cells. 29 In fact, metabolic and therapeutic stresses activate multiple signal transduction pathways and regulate cell death and cell survival in cancer cells. A detailed understanding of the mechanisms that are clinically relevant in leukemia might help to predict and overcome drug resistance thereby improving chemotherapy and ultimately the outcome of cancer patients.
There is now 'proof of principle' that blocking damageassociated molecular patterns through the HMGB1/receptor for advanced glycation end products and HMGB1/toll-like receptor axes, interferes with tumor growth kinetics in either a transplantable or spontaneous tumor models. 30, 31 We, and others, have found that patients with solid tumors (for example, gastric cancer, colon cancer, lung cancer, cervical cancer and hepatocellular carcinoma) or leukemia (for example, childhood acute lymphocytic leukemia) have elevated serum levels of HMGB1 and downstream markers of endogenous damage-associated molecular pattern-induced inflammatory responses. 9, 32, 33 Here, we observe that HMGB1 was elevated in the supernatants of leukemia cell cultures after chemotherapy. Furthermore, the cytotoxicity induced by chemotherapy was enhanced by administration of an anti-HMGB1 antibody and HMGB1 inhibitor, suggesting that HMGB1 release increases drug resistance and diminishes chemotherapy-induced cytotoxicity. Indeed, neutralizing antibodies to HMGB1 decrease tumor incidence and size in colitis-associated cancer models. 34 Furthermore, ethyl pyruvate, a potent inhibitor of HMGB1 release, has significant antitumor activities in experimental liver tumor models. 35 Thus, the specific inhibition of circulating HMGB1, using neutralizing antibodies or specific antagonists, may improve the chemotherapy administered to cancer patients including those with leukemia.
Our experimental data suggest that HMGB1 increases drug resistance through regulation of autophagy. Recently, autophagy has been recognized as a programmed cell survival mechanism that is involved in the response to cytotoxic chemotherapy or irradiation and is responsible for drug resistance. 4 For example, loss of autophagy-related genes results in the sensitization of resistant carcinoma cells to radiation. 36 Autophagy inhibition with chloroquine, an inhibitor of fusion between the autophagosome and lysosome, has also been found to significantly delay the onset of spontaneous tumors in a transgenic mouse model of Myc-induced lymphoma. 5 Moreover, the therapeutic effects of the blockbuster leukemia drug, imatinib, are enhanced when given along with chloroquine in chronic myeloid leukemia cells. 23 Further, disrupting autophagy augments the anticancer activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in imatinib-resistant chronic myeloid leukemia. 24 Some controversy exists about the effect of autophagy on the fate of leukemia cells. For example, additional upregulation of autophagy by knockdown of mTOR dramatically improves vitamin D3 inhibition of leukemia cells. 37 However, it should be noted that mTOR acts as a central regulator of many biological processes, in addition to autophagy, that are essential for cell proliferation, angiogenesis and cell metabolism. 38 In contrast, knockdown of Beclin1 eliminates vitamin D3-induced autophagy and activates apoptosis. 37 We found that loss of Beclin1 or treatment with bafilomycin A1, an autophagy inhibitor, increased the sensitivity of leukemia cells to chemotherapy. These studies suggest that inhibition of HMGB1 and autophagy in leukemia L Liu et al autophagy potentiates chemotherapy-induced cell death in leukemia cells. Here we demonstrate that extracellular HMGB1 is a direct regulator of autophagy in leukemia cells thereby controlling LC3 conversion (LC3-I-LC3-II), degradation of p62 and maturation of autophagosomes. A recent study demonstrated that endogenous HMGB1 regulates autophagy by directly interacting with the autophagy protein Beclin1 and displacing Bcl-2, 11 supporting the role of HMGB1 in autophagy. Furthermore, HMGB1 potentially confers its proautophagic activities via the PI3K-MEK-ERK pathway. The PI3Ks, (PI3-kinase/PI3K), family is organized into three classes: I, II and III. PI3K-III activity is required for autophagy, whereas PI3K-I activity has an inhibitory effect on autophagy.
2 PI3K-III is the mammalian homolog of Vps34, first identified in yeast. The PI3K-III complex is required to recruit the Atg12-Atg5 conjugate to the pre-autophagosomal structure, 39 a relatively early event during autophagy. One of the most commonly used pharmacological approaches to inhibit autophagy in vitro involves the use of PI3K inhibitors such as wortmannin, LY294002 or 3-MA. 2 We found that 3-MA inhibited HMGB1-induced LC3 conversion. However, it should be noted that all of these reagents can inhibit both PI3K-I and PI3K-III activity and target other kinases. 2 Indeed, genetic inhibition of PI3K-III by specific shRNA also inhibited HMGB1-induced autophagy, suggesting that PI3K-III activity is required for HMGB1-induced autophagy in leukemia cells.
Moreover, we found that extracellular signal-regulated protein kinase (ERK) functions as a downstream signal of PI3K to mediate HMGB1-induced autophagy. The tight interaction between PI3K and ERK has previously been demonstrated to regulate inflammation and protein synthesis. 40, 41 In leukemia cells, blockade of the PI3K or ERK signaling pathway enhances apoptosis in response to antileukemic drugs such as arsenic trioxide or histone deacetylase inhibitors. [42] [43] [44] It is well established that exogenous HMGB1 induces MEK-ERK activation in immune cells and cancer cells. 19, 22, 32, 45 Here, we found that 3-MA inhibited HMGB1-induced phosphorylation of ERK, indicating that ERK is a downstream signal of PI3K. Importantly, knockdown or pharmacological inhibition of MEK-ERK attenuated HMGB1-induced LC3 conversion, suggesting that MEK-ERK is also required for HMGB1-induced autophagy in leukemia cells. Indeed, inhibition of ERK attenuates autophagy and potentiates tumor necrosis factor-a-induced cell death in breast cancer cells. 46 A recent study also demonstrated that the MEK-ERK signaling pathway regulates autophagy via directly regulating Beclin1, 47 the first identified mammalian gene with a role in mediating autophagy.
In summary, we show that HMGB1 is released in leukemia cell lines in response to chemotherapy and functions as a positive regulator of autophagy, which enhances resistance to anticancer therapies. As a damage-associated molecular pattern, HMGB1 activates the PI3K-MEK-ERK pathway, thereby regulating autophagosome formation and fusion of the autophagosome with the lysosome (Figure 6 ). In light of the therapeutic promise of autophagy inhibitors to render tumor cells more susceptible to conventional therapies, our discovery that HMGB1 is an important regulator of autophagy in leukemia cells may lead to the development of novel strategies for the treatment of human leukemias. 
